Aerie Pharmaceuticals, Inc.
17.29-0.85 (-4.69%)

After hours: 17.290.00 (0.00%) as of 4:31 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close18.14
Bid14.11 x 300
Ask20.00 x 100
52wk Range10.82 - 33.25
Day's Range17.27 - 18.34
Avg Vol (3m)351,914
As of 4:00 PM EDT. Market closed.
  • American City Business Journalslast month

    Aerie Pharma stays on track with late-stage trial enrollment

    Shares of Duke University spinout Aerie Pharmaceuticals (AERI) have been trending upward for the past month, this week notwithstanding, and the the drug developer announced favorable news Thursday morning that shows it is on track with a late-stage trial. Finding the right patients who are both willing and meet the proper profile for a clinical trial can be difficult, and reaching the enrollment milestone keeps Aerie on schedule for an interim trial readout in the fourth quarter. Aerie is developing an eye drop named Rhopressa as a treatment for glaucoma and announced that it has enrolled 700 patients in a Phase 3 clinical trial in which it is testing Rhopressa against the existing treatment timolol.

  • Benzingalast month

    Aerie Completes Enrollment Of Rocket 4 Final Stage Clinical Study Of RhopressaTM 0.02%

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) disclosed the completion of patient enrollment in Rocket 4, its final stage clinical study for RhopressaTM (netarsudil ophthalmic solution) 0.02% intended to ...